NYXH Stock Overview
A medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Nyxoah S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.28 |
| 52 Week High | €20.00 |
| 52 Week Low | €4.00 |
| Beta | 0.55 |
| 11 Month Change | -14.37% |
| 3 Month Change | 0.61% |
| 1 Year Change | 62.35% |
| 33 Year Change | -59.61% |
| 5 Year Change | n/a |
| Change since IPO | -65.50% |
Recent News & Updates
Shareholder Returns
| NYXH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.8% | 1.7% | 0.3% |
| 1Y | 62.4% | 21.4% | 31.1% |
Return vs Industry: NYXH exceeded the US Medical Equipment industry which returned 20.3% over the past year.
Return vs Market: NYXH exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| NYXH volatility | |
|---|---|
| NYXH Average Weekly Movement | 5.7% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NYXH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NYXH's weekly volatility has decreased from 15% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 147 | Olivier Taelman | www.nyxoah.com |
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A. Fundamentals Summary
| NYXH fundamental statistics | |
|---|---|
| Market cap | US$309.62m |
| Earnings (TTM) | -US$55.53m |
| Revenue (TTM) | US$5.33m |
58.1x
P/S Ratio-5.6x
P/E RatioIs NYXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYXH income statement (TTM) | |
|---|---|
| Revenue | €5.08m |
| Cost of Revenue | €1.94m |
| Gross Profit | €3.14m |
| Other Expenses | €56.12m |
| Earnings | -€52.98m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 13, 2025
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 61.77% |
| Net Profit Margin | -1,042.50% |
| Debt/Equity Ratio | 18.7% |
How did NYXH perform over the long term?
See historical performance and comparison